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INTRODUCTION
Beh et’ s disease (BD) is a multisystemic inflammatory dis-
order characterized by recurrent oral and genital ulcers, and
ocular, joint, and skin lesions. Involvement of the gastroin-
testinal tract, central nervous system, or pulmonary vascula-
ture is less common, but accounts for the majority of mor-
tality associated with the disease (1, 2). BD has a worldwide
distribution but its prevalence and severity are geographical-
ly variable. Although its etiology and pathogenesis remains
unclear, its onset is believed to be triggered by the involve-
ment of some external factors in individuals with a particu-
lar genetic background (1, 3-7). 
BD is known to be associated with HLA-B51 in many
different ethnic groups. MHC class I chain-related genes A
(MICA) located only 46 kb centromeric of the HLA-B gene,
has been identified within the class I region (3-9). Expression
of MICA has been detected in fibroblast and epithelial cell
lines, gastrointestinal epithelium, keratinocytes, endothelial
cells, and monocytes (10, 11). The MICA gene is regulated
by promoter heat shock elements similar to those of the hsp70
genes (9). An association with MICA and BD has been report-
ed with a triplet repeat microsatellite polymorphism (GCT/
AGC)n in the transmembrane (TM) region of the MICA gene
(3-6, 8). The six (GCT) repetition (MICA*A6) was present in
significantly more BD patients than controls in the Japanese,
Middle Eastern, and Greek populations (1, 3, 4, 12, 13). On
the other hand, there was a lack of association between the
MICA TM region polymorphism and BD in the Spanish and
Italian populations (14, 15). The MICA microsatellite poly-
morphism exhibit a strong linkage disequilibrium with the
HLA-B locus. Therefore, the roles (primary versus secondary)
of polymorphism of the MICA molecule in the susceptibili-
ty and the severity of BD are still unclear. 
We investigated the microsatellite polymorphism of the
MICA gene in Korean patients with BD and analyzed the
relationship between these polymorphisms and HLA-B51
and the clinical manifestations.
MATERIALS AND METHODS
Patients and controls
One-hundred and eight Korean patients with BD and 204
ethnically matched healthy controls were enrolled in this study.
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Association of MICA Polymorphism with HLA-B51 and Disease 
Severity in Korean Patients with Behcet's Disease
The HLA-B51 allele is known to be associated with Beh et’s disease (BD) in many
ethnic group. However, it has not yet been clarified whether the HLA-B51 gene
itself is the pathogenic gene related to BD or whether it is some other gene in linkage
disequlibrium with HLA-B51. Recently, the Triplet repeat (GCT/AGC) polymorphism
in transmembrane region of the MHC class I chain-related A (MICA) gene was
identified. To investigate the association of MICA with BD, we studied the MICA
polymorphism in 108 Korean BD patients and 204 healthy controls in relation to
the presence of HLA-B51 and clinical manifestations. The triplet repeat polymor-
phism was determined by polymerase chain reaction (PCR)-denaturing polyacry-
lamide gel electrophoresis (PAGE). The phenotype frequency of the MICA*A6 allele
(relative risk, RR=2.15, p=0.002) and HLA-B51(RR=1.87, p=0.022) were signifi-
cantly increased in the Korean patients with BD. A strong linkage disequilibrium
was observed between the MICA*A6 and HLA-B51 in both the patients with BD and
control subjects. Stratification analysis showed that MICA*A6 homozygosity was
strongly associated with BD in the HLA-B51-negative population, and HLA-B51
was also associated with MICA*A6-negative population. In conclusion, MICA*A6
rather than HLA-B51 was strongly associated with Korean patients with BD, and
the MICA*A6 allele is a useful susceptibility marker of BD, especially in the HLA-
B5-negative subjects. 
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,
,BD was diagnosed and classified according to the criteria pro-
posed by the International Beh et’ s disease study group (16).
The mean age of the patients was 41.2 yr (range, 21-62 yr)
and the mean duration of the disease was 3.8 yr (range, 0.4-
25.5 yr). This study was performed in accordance with the
Declaration of Helsinki. 
DNA extraction
DNA was prepared from peripheral blood cells of patients
and controls by salting out of cellular proteins and alcohol
precipitation.
HLA-B typing
HLA-B typing was performed using the ARMS (amplifi-
cation-refractory mutation system)-PCR (polymerase chain
reaction) method (17). Each tube contained a primer mix
consisting of the allele- or group-specific primer pairs and a
positive control primer, which matched the non-allelic se-
quences. HLA-B typing included 39 sets of primer mixtures.
PCR reactions were performed in a volume of 13  L as mod-
ified in the class I ARMS-PCR reference manual of the 12th
International Histocompatibility Workshop. The PCR pro-
duct size was defined on 1.5% agarose gel pre-stained with
ethidium bromide. 
MICA transmembrane region analysis
For analysis of the microsatellite repeat polymorphism in the
TM region of the MICA gene, PCR primers flanking the TM
region (MIC-A5F, 5′ -CCTTTTTTTCAGGGAAAGTGC-
3′ ; MIC-A5R, 5′ -CCTTACCATCTCCAGAAACTGC-3′ )
were designed. The MIC-A5R primer corresponds to the in-
tron 4 and exon 5 boundary region and MIC-A5F is located
in the intron 5. PCR conditions and purification were per-
formed as described by Mizuki et al. (6).
PCR was carried out in a Perkin Elmer 9600 Thermal
Cycler with mixtures consisting of 40 ng of genomic DNA,
10×PCR buffer (10 mM Tris-HCl, pH 8.3, 40 mM KCl, and
15 mM MgCl2, Bioneer, Korea), 250  M dNTPs (Bioneer),
10 pmole of each primer (Bioneer), and 1 U of Taq polymerase
(Bioneer). Amplified products were mixed with equal volumes
of denaturing solution (95% formamide, 20 mM EDTA,
0.05% bromophenol blue, and 0.05% xylene cyanol FF). The
mixtures were denatured at 95℃ for 2 min. Five microliters
of each of the mixtures was loaded onto a 6% denaturing
polyacrylamide gel. Polymorphic fragments in the gel were
visualized by silver staining. Single-strand conformational
polymorphism analysis was applied to determine the one-or
two-base differences in the MICA alleles (MICA 5, MICA
5.1, and MICA 6) as described by Choi et al. (18). 
Statistical analysis
The gene and phenotype frequencies were estimated by
direct counting. The significance of the distribution of alle-
les between the patients with BD and healthy controls was
examined using the chi-square ( 2) and Fisher’ s exact proba-
bility tests. Relative risk (RR) were calculated using Woolf ’ s
method (19). The relative (primary vs secondary) importance
of the MICA and HLA-B51 alleles in terms of the suscepti-
bility to BD was determined using the methods described
by Svejgaard and Ryder (20).
RESULTS
Analysis of the data demonstrated that the gene frequency
of the MICA*A6 allele was significantly increased in BD pa-
tients, as compared with healthy controls (45.8% vs 26.5%,
RR=2.35, p<0.001), and that the MICA*A5.1 allele was
significantly decreased in BD patients (4.2% vs 19.1%, RR=
0.18, p<0.001) (Table 1). The phenotype frequency of the
MICA*A6 allele was significantly higher in BD than in con-
trol (63.9% vs 45.1%, RR=2.15, p=0.002). Furthermore,
the phenotype frequency of those homozygous for the MICA*
A6 allele was more strongly associated with BD (27.8% vs
4.8%, RR=4.52, p<0.001) than that of those heterozygous
for MICA*A6 allele (Table 2). Thirty-eight of the 108 BD
patients were HLA-B*51 positive (35.2%), as compared with
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A4 19 (8.8) 53 (13.0) NS*
A5 60 (27.7) 107 (26.2) NS
A5.1 9 (4.2) 78 (19.1) < 0.001 0.18
A6 99 (45.8) 108 (26.5) < 0.001 2.35
A9 29 (13.4) 62 (15.2) NS
BD, Beh et’s disease ; RR, relative risk; *NS, not significant.
Microsatellite 
allele
BD
n=216 (%)
Control
n=408 (%) p value RR
Table 1. Gene frequencies of the microsatellite polymorphism
in the transmembrane region of the MICA gene in patients with
Beh et’s disease
A4 14 (13.0) 49 (24.0) 0.026 0.47
A5 51 (47.2) 91 (44.6) NS*
A5.1 7 (6.5) 64 (31.4) < 0.001 0.15
A6 69 (63.9) 92 (45.1) 0.002 2.15
A6/A6 30 (27.8) 16 (4.8) < 0.001 4.52
A9 29 (26.9) 57 (27.9) NS
HLA-B51 38 (35.2) 46 (22.5) 0.022 1.87
BD, Beh et’s disease ; RR, relative risk; *NS, not significant.
Microsatellite 
allele
BD
n=108 (%)
Control
n=204 (%) p value RR
Table 2. Phenotype frequencies of the microsatellite poly-
morphism in the TM region of the MICA gene in patients with
Beh et’s disease46 of 204 controls (22.5%) (RR=1.87, p=0.022) (Table 2). 
The MICA*A6 allele was present in most (89.5%) of the
HLA B51-positive patients and in additional 35 (50.0%) B51-
negative patients. Thirty-four of the 69 MICA*A6-positive
patients had HLA-B*51 and 4 of the 39 MICA*A6-negative
patients had HLA- B*51 (Table 3).
Therefore, to elucidate which allele, MICA*A6 or HLA-
B*51, has the stronger association with BD, the association
of the MICA*A6 allele with BD, after stratification for the
effect of HLA-B51, was estimated. The MICA*A6 allele was
significantly associated with BD (RR=2.29, p=0.007). On the
other hand, when we estimated the association of HLA-B51
with BD after stratification for the effect of MICA*A6 allele,
a significant association between B51 and BD was observed
(RR=6.29, p=0.039) (Table 3). The susceptibility risk of the
MICA*A6 homozygosity for BD was elevated in the HLA-
B51-negative patients (RR=21.27, p<0.001) (Table 4). Our
results suggest that the MICA*A6 allele, rather than HLA-
B51, is strongly associated with BD in Korea and an useful
susceptibility marker for BD, especially in the HLA-B51-
negative Korean population.
However, most of the B51-positive patients (89.5%) and
B51-positive healthy controls (95.7%) possessed the MICA
*A6 allele, demonstrating a strong linkage disequilibrium
of MICA*A6 and HLA-B51. 
We analyzed clinical manifestations according to the MICA
gene polymorphism and the presence of HLA-B51. As is sum-
marized in Table 5, patients with MICA*A6 tended to show
intestinal and ocular involvement more frequently, but this
was not statistically significant.
Involvement of the gastrointestinal tract, central nervous
system (CNS), ocular and vascular systems is related with poor
prognosis of BD. Therefore, the clinical manifestations with
the involvement of those systems were considered to be severe
complications of BD.
The frequency of the MICA*A9 allele was no different be-
tween BD and the controls, whereas patients with MICA
*A9 had less severe BD complications, in terms of uveitis,
thrombosis, and intestinal involvement, than those without
(Table 5). However, no associations were observed between
the clinical features and HLA-B*51 (data not shown).
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*p=0.007, RR=2.29 ; 
� p=0.039, RR=6.29. BD, Beh et’s disease ; RR,
relative risk.
HLA-B51 + - + -
BD 34 35 4 35
Control 44 48 2 110
B. Association between BD and HLA-B51 in the presence or absence
of MICA*A6 allele
MICA*A6 allele
positive
MICA*A6 allele 
negative
�
MICA*A6 + - + -
BD 34 4 35 35
Control 44 2 48 110
A. Association between BD and MICA*A6 allele in the presence or
absence of HLA-B51
HLA-B51 positive HLA-B51 negative*
Table 3. Association of MICA*A6 allele and HLA-B51 with
susceptibility to Beh et’s disease
*p<0.001, RR=21.27;  
� p=0.023, RR=0.143; 
� p=0.030, RR=2.04. BD,
Beh et’s disease; RR, relative risk.
HLA-B51 + - + -
BD 15 15 23 55
Control 14 2 32 156
B. Association between BD and HLA-B51 in the presence or absence
of MICA*A6/A6
MICA*A6/A6 positive
� MICA*A6/A6 negative
�
MICA*A6/A6 + - + -
BD 15 23 15 55
Control 14 32 2 156
A. Association between BD and MICA*A6/A6 in the presence or
absence of HLA-B51
HLA-B51 positive HLA-B51 negative*
Table 4. Association of MICA*A6 homozygote and HLA-B51
with susceptibility to Beh et’s disease
Oral ulcer 69 (100) 39 (100) 29 (100) 79 (100)
Genital ulcer 40 (58.0) 25 (64.1) 18 (62.1) 47 (59.5)
Skin lesion 41 (59.4) 26 (66.7) 19 (65.5) 48 (60.8)
Arthritis 37 (53.6) 25 (64.1) 16 (55.2) 46 (58.2)
Uveitis 28 (40.6) 11 (28.2) 8 (27.6) 31 (39.2)
GI lesion 6 (8.7) 1 (2.6) 0 (0.0) 7 (8.9)
CNS lesion 3 (4.3) 2 (5.1) 1 (3.4) 4 (5.1)
Thrombosis 4 (5.8) 2 (5.1) 1 (3.4) 5 (6.3)
Complicated form* 31 (44.9) 14 (35.9) 8 (27.6)
� 45 (53.2)
*uveitis/CNS/GI/thrombosis; 
� p=0.018. GI lesion, gastrointestinal lesion;
CNS lesion, central nervous system lesion.
Clinical 
manifestations positive
n=69 (%)
MICA*A6 MICA*A9
negative
n=39 (%)
positive
n=69 (%)
negative
n=39 (%)
Table 5. Clinical association of MICA*A6 and MICA*A9 allele
in Beh et’s disease
Korean A6 2.35 < 0.001 Park et al. (Persent  study)
Japanese A6 2.70 0.00041 Mizuki et al. (13)
Jordanian A6 4.39 0.005 Mizuki et al. (12)
Greek A6 2.93 0.013 Yabuki et al. (5)
Italian A6 NS Salvarani et al. (15)
Spanish A6 NS Gonzalez-Escribano et al. (14)
RR, relative risk.
Popula-
tions
Microsatellite
alleles
References p value RR
Table 6. Association of MICA TM region polymorphisms and
Beh et’s disease in the different populations DISCUSSION
It is well established that BD is associated with the HLA-
B51 molecule that has a relatively high incidence, which
ranges from 36.3% to 76.9% in many ethnic groups includ-
ing the Asian and Eurasians (1, 12, 21). In our study, the
prevalence of HLA-B51 was found to be significantly in-
creased in patients with BD (35.2% vs 22.5%). 
In the present study, we demonstrate that the MICA*A6
allele is significantly associated with the susceptibility to BD,
as was shown by the previous data on Japanese population
(6). However, the MICA*A6 allele is not associated with BD
in some ethinic groups (Table 6).
Mizuki et al. suggested that a genetic predisposition to BD
appears to play an important role with a strong association
with the MICA gene rather than HLA B51 (6), but a recent
report has suggested that the real pathogenic gene for BD is
the HLA-B gene itself and the HLA-B*51 allele is the major
susceptibility gene responsible for the development of BD
(4, 13, 15, 22). Therefore, we cannot be certain whether HLA-
B51 itself or a closely linked gene is responsible for the sus-
ceptibility to BD.
In the present study, an association was observed between
the MICA*A6 allele and BD, and also observed between
HLA-B51 and BD. After stratification for the effect of HLA-
B51, the MICA*A6 allele was significantly associated with
BD. After stratification for the effect of the MICA*A6 allele,
the association between HLA-B51 and BD was observed in
the MICA*A6 allele-negative patients. We observed a strong
linkage disequilibrium of MICA*A6 and HLA-B51. Our
results suggest that the MICA-A6 allele rather than the HLA-
B51 allele is strongly associated with Korean BD and an use-
ful susceptibility marker for BD, especially in the HLA-B51-
negative Korean population.
The etiologic role of the polymorphism in the MICA mol-
ecules is still unknown. Enhanced T cell proliferative response
to the mycobacterial 65-kDa heat shock protein (hsp) peptides
and their homologous peptides derived from human 60-kDa
hsp have been demonstrated in patients with BD (23). An
increased number of  T cells preferentially respond to hsp65
in the peripheral blood and the involved tissues from patients
with BD, and a phenotypically distinct subset of the  T
cells, CD45RA+CD45RO-Vgamma9+Vdelta2+, may con-
tribute to the immunological abnormalities, which in turn,
probably lead to the complex pathophysiology of Beh et’ s
disease (24-27). T cells expressing the V 1 receptor form 70-
90% of  T cells in the intestinal epithelium, where MICA
is also expressed (1). It has also been reported that MICA*A6
may tend to activate V 1 T cells more effectively via spe-
cific interaction with  T cells, because of either the presence
of specific amino acids in the a1/a2 domains linked to MICA*
A6 or that of a particular V 1  T-cell repertoire that can
recognize the MICA molecule with MICA*A6 in an efficient
way (5, 27). 
In our study, the MICA*A6 allele was present in six of the
seven patients with intestinal involvement, more specifically
those that had experienced episodes of intestinal hemorrhage
or ulcer. This result could be explained by the more effective
activation of  T cells of the intestinal epithelium by MICA*
A6 than by other MICA alleles. Patients with the MICA*A6
allele tended to show intestinal and ocular involvement more
frequently, whereas patients with MICA*A9 had less severe
BD complications, in terms of uveitis, thrombosis, neurologi-
cal, and intestinal involvement, than those without MICA*
A9. Although the prevalence of severe complications associ-
ated with BD was low in our study group, it seems that the
polymorphism of the MICA-TM allele is related with the
clinical manifestations and severity of Korean patients with
BD. 
Recently, a MICA genotyping study showed a strong asso-
ciation between the MICA009 allele and BD in the Japanese
population. In this study, the MICA gene was found not to
be directly involved in the pathogenesis of BD (4). Further
study is required to elucidate the role of the MICA gene in
the development and severity of BD. 
In summary, the MICA*A6 allele is a useful susceptibility
marker for BD, especially in the HLA-B51- negative Korean
population, and that the MICA gene polymorphism rather
than that of HLA-B51 is strongly associated with the sus-
ceptibility to BD in the Korean population. Moreover, it is
believed that the MICA gene polymorphism may play an
important role in the severity of BD in the Korean popula-
tion.
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